Harrison 2025 - Pemvidutide in MASLD: Randomized Phase 2 Trial

Journal of Hepatology·January 1, 2025

Stephen A. Harrison

Summary

Pemvidutide significantly reduced liver fat content, hepatic inflammatory activity, and body weight, supporting development for MASH and obesity-related liver disease.

Study Details

Study Design

Randomized, double-blind, placebo-controlled phase 2 trial

Indication

Metabolic dysfunction-associated steatotic liver disease / liver fat reduction

Intervention

Once-weekly pemvidutide vs placebo

Species

Human

Risk of Bias Assessment

Sponsor-funded phase 2 trial